Analysts are on the Bearish side about Celgene Corporation (NASDAQ:CELG) this week.

Celgene Corporation (NASDAQ:CELG) Logo
Investors sentiment increased to 0.76 in Q1 2019. Its up 0.12, from 0.64 in 2018Q4. It is positive, as 108 investors sold Celgene Corporation shares while 441 reduced holdings. 204 funds opened positions while 213 raised stakes. 482.72 million shares or 1.75% less from 491.33 million shares in 2018Q4 were reported.
Jpmorgan Chase holds 7.05 million shares or 0.14% of its portfolio. Soros Fund Mgmt Ltd Liability Corp has invested 0.89% of its portfolio in Celgene Corporation (NASDAQ:CELG). Perigon Wealth Lc stated it has 31,954 shares. Abrams Capital Mngmt Lp invested in 6.75 million shares. Mufg Americas Holdings Corp holds 0.28% or 103,944 shares in its portfolio. 233,779 were reported by Zwj Invest Counsel Inc. Moreover, Factory Mutual has 0.55% invested in Celgene Corporation (NASDAQ:CELG) for 490,500 shares. Everence Capital Incorporated invested 0.32% in Celgene Corporation (NASDAQ:CELG). Raymond James Assocs holds 388,093 shares. Scotia Cap Incorporated reported 26,441 shares. First Foundation Advsrs holds 3,090 shares. Augustine Asset Management invested in 2.38% or 37,951 shares. Macroview Management Ltd Liability Corp owns 24 shares. Jet Cap Limited Partnership reported 500,909 shares or 9.65% of all its holdings. Amica Mutual accumulated 35,364 shares.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 5 analysts covering Celgene (NASDAQ:CELG), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Celgene has $103 highest and $95 lowest target. $100.20’s average target is 7.38% above currents $93.31 stock price. Celgene had 16 analyst reports since February 26, 2019 according to SRatingsIntel. The firm has “Hold” rating by Cantor Fitzgerald given on Monday, June 24. The stock has “Buy” rating by Robert W. Baird on Tuesday, March 12. The firm has “Buy” rating given on Thursday, February 28 by Jefferies. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, February 28. The company was maintained on Monday, June 24 by Mizuho. Robert W. Baird maintained it with “Buy” rating and $101 target in Thursday, February 28 report. Below is a list of Celgene Corporation (NASDAQ:CELG) latest ratings and price target changes.

24/06/2019 Broker: Mizuho Rating: Buy New Target: $103 Maintain
24/06/2019 Broker: Cantor Fitzgerald Rating: Hold New Target: $100 Maintain
03/05/2019 Broker: BidaskScore Rating: Hold Upgrade
03/05/2019 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
26/04/2019 Broker: BidaskScore Rating: Sell Downgrade
05/04/2019 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Neutral Downgrade
01/04/2019 Broker: Bernstein Old Rating: Outperform New Rating: Market Perform Downgrade
01/04/2019 Broker: UBS Old Rating: Buy New Rating: Neutral Downgrade
01/04/2019 Broker: Atlantic Securities Old Rating: Overweight New Rating: Neutral Downgrade
26/03/2019 Broker: Canaccord Genuity Rating: Hold Maintain

The stock increased 0.45% or $0.42 during the last trading session, reaching $93.31. About 2.19 million shares traded. Celgene Corporation (NASDAQ:CELG) has risen 3.32% since August 15, 2018 and is uptrending. It has outperformed by 3.32% the S&P500.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $66.13 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 12.75 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: which released: “Bristol-Myers Squibb Stock Has Upside — But Mind the Risks – Nasdaq” on August 12, 2019, also with their article: “Agios Rides High on Tibsovo Sales Amid Acute Competition – Nasdaq” published on August 15, 2019, published: “Seth Klarman Buys XPO Logistics, Exits 3 Positions in 2nd Quarter – Yahoo Finance” on August 14, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: and their article: “Block & Leviton Announces $55 Million Settlement in Antitrust Case Against Celgene – GlobeNewswire” published on July 24, 2019 as well as‘s news article titled: “Top Stock Reports: Micron, Sinopec, Celgene & More – Nasdaq” with publication date: August 13, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.